Impact Biomedical Inc. priced its initial public offering at $3.00 a share, to list on the NYSE American under the symbol IBO. It has a Form S-1 registration statement on file for an initial public offering. As of November 6, 2026, its final prospectus is on file (Form 424B4, September 17, 2024).
Sell to companies like Impact Biomedical Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
Impact Biomedical Inc. has a Form S-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-08-09. Amendments on record here: 3. It filed its final prospectus on 2024-09-17, at a public offering price of $3.00 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our shares of common stock have been approved for listing and trading on the NYSE American under the symbol “IBO”.From the 424B4 filed 2024-09-17
Shares offered
Similarly, each increase (decrease) of 1,000,000 shares in the number of common stock we are offering would increase our pro forma net tangible book value by approximately $2,760,000, or $0.31 per share and decrease the dilution per share to new investors participating in this offering by $0.31 per share, assuming that the public offering price of $3.00 remains the same, and after deducting the estimated underwriting discounts and commissions.From the 424B4 filed 2024-09-17
Offering price
on a pro forma basis to give effect to the sale of 1,500,000 shares in this offering at a public offering price of $3.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.From the 424B4 filed 2024-09-17
Use of proceeds
We currently intend to use the net proceeds received from this offering for general and working capital purposes, including but not limited to investing in research and development, including in our technology, the repayment of debt and for other working capital and general corporate purposes.From the 424B4 filed 2024-09-17
Net loss or income
For the year ended December 31, 2023, the Company recorded net losses of $4,407,000, as compared to net losses of $7,255,000 for the year ended December 31, 2022.From the S-1/A filed 2024-08-20
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-08-09 | Registration statement amended | S-1/A |
| 2024-08-20 | Registration statement amended | S-1/A |
| 2024-08-27 | Registration statement amended | S-1/A |
| 2024-09-17 | Final prospectus filed: the offering is priced | 424B4 |
Check before you invest in Impact Biomedical Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Impact Biomedical Inc. and the records around it.
Also filing to list on the NYSE American
IPO filings on the NYSE American in Q3 2024, newest first.
- Legacy Education Inc. (Sep 2024)
Watch Impact Biomedical Inc.
Get an email when Impact Biomedical Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Impact Biomedical Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Impact Biomedical Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Impact Biomedical Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Tools for this story
Each opens in a new tab, filled in for Impact Biomedical Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.